Salem Investment Counselors Inc. Increases Position in Tempus AI, Inc. $TEM

Key Points

• Salem Investment Counselors Inc. significantly increased its stake in Tempus AI, Inc. by 8,020.0%, acquiring a total of 30,450 shares valued at approximately $1.93 million.
• Several analysts have recently issued positive ratings for Tempus AI, with price targets elevated, notably by HC Wainwright raising it to $98.00 and BTIG Research to $85.00, suggesting strong market confidence.
• CEO Eric P. Lefkofsky sold 332,500 shares at an average price of $74.10, which reduced his ownership by 3.49%, indicating possible profit-taking amidst positive stock performance.

Salem Investment Counselors Inc. grew its holdings in shares of Tempus AI, Inc. (NASDAQ:TEM - Free Report) by 8,020.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 30,450 shares of the company's stock after acquiring an additional 30,075 shares during the period. Salem Investment Counselors Inc.'s holdings in Tempus AI were worth $1,935,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Pathway Capital Management LP acquired a new stake in Tempus AI during the 1st quarter worth about $8,576,000. SeaCrest Wealth Management LLC acquired a new stake in Tempus AI during the 1st quarter worth about $535,000. Sumitomo Mitsui Trust Group Inc. grew its holdings in Tempus AI by 31.4% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,255,477 shares of the company's stock worth $205,284,000 after acquiring an additional 1,016,384 shares during the period. Massachusetts Financial Services Co. MA grew its holdings in Tempus AI by 92.6% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 578,890 shares of the company's stock worth $27,926,000 after acquiring an additional 278,311 shares during the period. Finally, Cambridge Investment Research Advisors Inc. acquired a new stake in Tempus AI during the 1st quarter worth about $1,019,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Tempus AI

In other Tempus AI news, Director Theodore Leonsis sold 44,000 shares of Tempus AI stock in a transaction dated Wednesday, August 13th. The stock was sold at an average price of $69.90, for a total transaction of $3,075,600.00. Following the completion of the transaction, the director owned 86,756 shares in the company, valued at approximately $6,064,244.40. The trade was a 33.65% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO James William Rogers sold 7,528 shares of the business's stock in a transaction that occurred on Tuesday, August 19th. The stock was sold at an average price of $74.65, for a total value of $561,965.20. Following the completion of the transaction, the chief financial officer owned 138,473 shares in the company, valued at $10,337,009.45. The trade was a 5.16% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 851,787 shares of company stock worth $60,009,768. 26.27% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of analysts have weighed in on TEM shares. Morgan Stanley increased their price target on Tempus AI from $65.00 to $68.00 and gave the stock an "overweight" rating in a report on Tuesday, August 12th. Guggenheim raised their target price on Tempus AI from $65.00 to $75.00 and gave the company a "buy" rating in a research note on Monday, June 30th. Needham & Company LLC restated a "buy" rating and issued a $70.00 target price on shares of Tempus AI in a research note on Friday, August 8th. BTIG Research raised their target price on Tempus AI from $75.00 to $85.00 and gave the company a "buy" rating in a research note on Wednesday, August 20th. Finally, HC Wainwright raised their target price on Tempus AI from $90.00 to $98.00 and gave the company a "buy" rating in a research note on Friday. Seven analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $70.17.

Tempus AI Stock Down 1.4%

TEM stock traded down $1.25 during mid-day trading on Monday, reaching $85.13. 5,159,392 shares of the company traded hands, compared to its average volume of 12,276,313. The stock has a market cap of $14.79 billion, a price-to-earnings ratio of -71.54 and a beta of 5.07. The company has a quick ratio of 1.43, a current ratio of 1.54 and a debt-to-equity ratio of 2.58. Tempus AI, Inc. has a fifty-two week low of $31.36 and a fifty-two week high of $91.45. The firm's 50 day moving average price is $67.61 and its 200 day moving average price is $59.62.

Tempus AI (NASDAQ:TEM - Get Free Report) last released its quarterly earnings results on Friday, August 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.01. The business had revenue of $314.64 million during the quarter, compared to the consensus estimate of $296.84 million. Tempus AI had a negative return on equity of 122.86% and a negative net margin of 20.98%.The company's quarterly revenue was up 89.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($6.86) EPS. Tempus AI has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Tempus AI, Inc. will post -6.15 EPS for the current fiscal year.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.